AU4988997A - Compositions and methods for treating bone deficit conditions - Google Patents

Compositions and methods for treating bone deficit conditions

Info

Publication number
AU4988997A
AU4988997A AU49889/97A AU4988997A AU4988997A AU 4988997 A AU4988997 A AU 4988997A AU 49889/97 A AU49889/97 A AU 49889/97A AU 4988997 A AU4988997 A AU 4988997A AU 4988997 A AU4988997 A AU 4988997A
Authority
AU
Australia
Prior art keywords
compositions
methods
treating bone
deficit conditions
bone deficit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49889/97A
Inventor
Nand Baindur
Scott M. Harris
Laurence H. Hurley
Sean M. Kerwin
Maria Kontoyianni
Gregory R Mundy
Mark W. Orme
Charles Petrie
Kirk G. Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Original Assignee
Zymogenetics Inc
OsteoScreen Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, OsteoScreen Inc, University of Texas at Austin filed Critical Zymogenetics Inc
Publication of AU4988997A publication Critical patent/AU4988997A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU49889/97A 1996-10-23 1997-10-23 Compositions and methods for treating bone deficit conditions Abandoned AU4988997A (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US73631896A 1996-10-23 1996-10-23
US73587096A 1996-10-23 1996-10-23
US73622296A 1996-10-23 1996-10-23
US73622196A 1996-10-23 1996-10-23
US73588196A 1996-10-23 1996-10-23
US73587396A 1996-10-23 1996-10-23
US73587496A 1996-10-23 1996-10-23
US73622896A 1996-10-23 1996-10-23
US73631996A 1996-10-23 1996-10-23
US73622096A 1996-10-23 1996-10-23
US73587696A 1996-10-23 1996-10-23
US08735881 1996-10-23
US08736222 1996-10-23
US08736221 1996-10-23
US08735876 1996-10-23
US08736319 1996-10-23
US08735873 1996-10-23
US08735870 1996-10-23
US08736318 1996-10-23
US08736220 1996-10-23
US08736228 1996-10-23
US08735874 1996-10-23
PCT/US1997/018864 WO1998017267A1 (en) 1996-10-23 1997-10-23 Compositions and methods for treating bone deficit conditions

Publications (1)

Publication Number Publication Date
AU4988997A true AU4988997A (en) 1998-05-15

Family

ID=27582807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49889/97A Abandoned AU4988997A (en) 1996-10-23 1997-10-23 Compositions and methods for treating bone deficit conditions

Country Status (4)

Country Link
EP (1) EP0973513A4 (en)
JP (1) JP2001510450A (en)
AU (1) AU4988997A (en)
WO (1) WO1998017267A1 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
JP2000513324A (en) * 1995-10-23 2000-10-10 ザイモジェネティクス，インコーポレイテッド Compositions and methods for treating bone defect conditions
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6369091B1 (en) 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
CZ20004350A3 (en) * 1998-05-22 2002-02-13 Avanir Pharmaceuticals Benzimidazole derivatives functioning as IgE modulators
US6303645B1 (en) 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
JP4533534B2 (en) * 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Inhibitor of glycogen synthase kinase 3
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DE60037394T2 (en) 1999-01-29 2009-01-02 The Board Of Trustees For The University Of Illinois, Urbana USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS IN CANCER THERAPY
CN1353605A (en) * 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof
WO2000078351A1 (en) * 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
AU6865100A (en) * 1999-09-02 2001-04-10 Mitsubishi Pharma Corporation Osteogenesis promoting agents
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
JP5278983B2 (en) * 1999-11-17 2013-09-04 塩野義製薬株式会社 New uses of amide compounds
US6794389B2 (en) 2000-03-31 2004-09-21 Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
ES2536449T3 (en) * 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Thioflavin derivatives for use in the diagnosis of Alzheimer's disease
ATE369853T1 (en) 2001-03-12 2007-09-15 Avanir Pharmaceuticals BENZIMIDAZOLE DERIVATIVES FOR IGE MODULATION AND CELL PROLIFERATION INHIBITION
US6696039B2 (en) 2001-04-23 2004-02-24 Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US8354397B2 (en) * 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
UA83620C2 (en) 2001-12-05 2008-08-11 Уайт Substituted benzoxazoles and analogues as estrogenic agents
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
DK1478358T3 (en) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylate for the treatment of diseases characterized by abnormal angiogenesis
EP1500652A4 (en) 2002-04-26 2006-05-03 Nippon Shinyaku Co Ltd Quinazoline derivative and medicine
SE0202134D0 (en) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
US7247741B2 (en) 2005-01-21 2007-07-24 Ptc Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
WO2004009533A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CA2504448C (en) * 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
PT1626714E (en) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diaryl ureas for diseases mediated by pdgfr
ES2297490T3 (en) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation OMEGA-CARBOXIARILDIFENILUREA FLUORO REPLACED FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS.
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
FR2860431A1 (en) * 2003-10-02 2005-04-08 Oreal Use of phenylazo benzene, pyridine or pyridazine derivatives as agents for inducing and/or stimulating growth of human keratinic fibers and/or inhibiting their loss and/or increasing their density
ITTO20040125A1 (en) * 2004-03-01 2004-06-01 Rotta Research Lab NEW HETEROCYCLIC AMIDINS INHIBITIVE THE PRODUCTION OF NITROGEN OXIDE (NO) FOR ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
BRPI0510305A (en) 2004-04-30 2007-10-02 Takeda Pharmaceutical compound or a salt thereof, prodrug or a salt thereof, pharmaceutical agent, method of producing the compound or a salt thereof, matrix metalloproteinase inhibitor or a salt thereof or a prodrug thereof, method of inhibiting a metalloproteinase matrix, and use of a compound or salt thereof or a prodrug thereof
US20100063046A1 (en) * 2006-05-17 2010-03-11 Whitten Jeffrey P Tetracyclic imidazole analogs
JP5186303B2 (en) * 2008-07-31 2013-04-17 東京応化工業株式会社 Resist composition and resist pattern forming method
WO2012026491A1 (en) 2010-08-26 2012-03-01 国立大学法人京都大学 Pluripotent stem cell cardiomyocyte differentiation-promoting agent
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
CN102558091B (en) * 2011-12-22 2014-10-08 合肥工业大学 Benzothiazole derivative and application thereof
WO2013111875A1 (en) * 2012-01-27 2013-08-01 国立大学法人京都大学 Method for inducing differentiation of pluripotent stem cell into cardiac muscle
US9388138B2 (en) 2012-07-18 2016-07-12 University College Dublin National University Of Ireland, Dublin Anti-angiogenic compounds
CN102942515A (en) * 2012-10-22 2013-02-27 暨南大学 Ethane bridged indole compound, synthetic method and application thereof
WO2014136519A1 (en) 2013-03-08 2014-09-12 国立大学法人京都大学 Promoter of differentiation of pluripotent stem cell into myocardium, which comprises egf receptor inhibitor
WO2015182765A1 (en) 2014-05-30 2015-12-03 国立大学法人京都大学 Method for inducing myocardial differentiation of pluripotent stem cells using low-molecular compound
CN106188003B (en) * 2016-07-22 2019-01-22 清华大学深圳研究生院 Bis- target spot fluorescence probes of Cu2+ and Fe3+ based on chinoline backbone and its preparation method and application
CN112010846A (en) * 2019-05-30 2020-12-01 四川大学华西医院 Pyridine derivative and preparation method and application thereof
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU532512B2 (en) * 1979-09-07 1983-10-06 Upjohn and Horton Anti-allergenic compounds for bone mineral resorption
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5523309A (en) * 1995-03-10 1996-06-04 Eli Lilly And Company Benzofuran pharmaceutical compounds
US5622974A (en) * 1995-03-10 1997-04-22 Eli Lilly And Company α-substituted-3-benzyl-benzofurans
FR2733685B1 (en) * 1995-05-05 1997-05-30 Adir USE OF BENZOPYRANE DERIVATIVES FOR OBTAINING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO THE C1- / HC03-, NA + INDEPENDENT EXCHANGER
JP2000513324A (en) * 1995-10-23 2000-10-10 ザイモジェネティクス，インコーポレイテッド Compositions and methods for treating bone defect conditions
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
CA2258822A1 (en) * 1996-06-20 1997-12-24 Sean Kerwin Compounds and methods for providing pharmacologically active preparations and uses thereof

Also Published As

Publication number Publication date
EP0973513A1 (en) 2000-01-26
WO1998017267A1 (en) 1998-04-30
EP0973513A4 (en) 2003-03-19
JP2001510450A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
AU4988997A (en) Compositions and methods for treating bone deficit conditions
AU7471096A (en) Compositions and methods for treating bone deficit conditions
AU1831597A (en) Methods and compositions for inhibiting hexokinase
AU5439996A (en) Compositions and methods for treating pain
AU5081298A (en) Surgical method and composition therefor
AU9214398A (en) Compositions and methods for treating water
AU5407598A (en) Bone implant
AU2113295A (en) Novel compositions and methods for water treatment
IL129555A0 (en) Methods and compositions for stimulating neurite growth
AU7601198A (en) Natural composition for treating bone or joint inflammation
HUP9904697A3 (en) Methods and compositions for immunomodulation
AU6872498A (en) Method and composition for skin treatment
HUP9900960A3 (en) Disinfecting compositions and method for disinfecting surfaces
ZA9710248B (en) Methods and compositions for stimulating neurite growth.
ZA9710258B (en) Methods and compositions for stimulating neurite growth.
AU4165797A (en) Methods and compositions for the treatment of bone resorption disorders, including osteoporosis
AU4813197A (en) Compositions and methods for treating viral infections
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU2327599A (en) Compositions and methods for treating autoimmune diseases
EP1109548A4 (en) Compositions and methods for treating and preventing bone diseases using tocotrienols
AU2243797A (en) Methods and compositions for inhibiting hexokinase
AU4248597A (en) Methods and compositions for treating preterm labor
GB9621570D0 (en) Formulations and methods for inhibiting bone loss
AU1714697A (en) Method and composition for the treatment of osteoarthritis
AU5594398A (en) Methods and compositions for preventing and treating bone loss